

Guideline adherence and survival of patients with candidaemia in Europe: results from the ECMM Candida III multinational European observational cohort study

Martin Hoenigl, Jon Salmanton-García, Matthias Egger, Jean-Pierre Gangneux, Tihana Bicanic, Sevtap Arikan-Akdagli, Ana Alastruey-Izquierdo, Nikolai Klimko, Aleksandra Barac, Volkan Özenci, et al.

▶ To cite this version:

Martin Hoenigl, Jon Salmanton-García, Matthias Egger, Jean-Pierre Gangneux, Tihana Bicanic, et al.. Guideline adherence and survival of patients with candidaemia in Europe: results from the ECMM Candida III multinational European observational cohort study. The Lancet Infectious Diseases, 2023, 23 (6), pp.751-761. 10.1016/S1473-3099(22)00872-6. hal-04164281

HAL Id: hal-04164281 https://univ-rennes.hal.science/hal-04164281

Submitted on 21 Jul 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

1 Guideline adherence predicts Survival of Candidemia in Europe: Results from

2 the ECMM Candida III multinational European Observational Cohort Study

3

Martin Hoenigl, Prof, ^{1,2,3#}, Jon Salmanton-García, PhD,^{4,5}, Matthias Egger, MD,^{1,3}, Jean-Pierre Gangneux, 4 Prof, ⁶, Tihana Bicanic, MD,⁷, Sevtap Arikan-Akdagli, Prof, ⁸, Ana Alastruey-Izquierdo, PhD, ⁹, Nikolai 5 Klimko, Prof, ¹⁰, Aleksandra Barac, MD, ¹¹, Volkan Özenci, Prof, ^{12,13}, Eelco F. J. Meijer, MD, ^{14,15,1}, Nina 6 7 Khanna, MD,¹⁷, Matteo Bassetti, Prof, ^{18,19}, Riina Rautemaa-Richardson, MD,^{20,21}, Katrien Lagrou, Prof, ^{22,23}, Kai-Manuel Adam, MD,¹⁶, Emin Halis Akalin, Prof, ²⁴, Murat Akova, Prof, ²⁵, Valentina Arsic 8 Arsenijevic, MD, ²⁶, Avinash Aujayeb, MD, ²⁷, Ola Blennow, MD, ²⁸, Stéphane Bretagne, Prof, ²⁹, François 9 Danion, MD,³⁰, Blandine Denis, MD,³¹, Nick Alexander de Jonge, MD,³², Guillaume Desoubeaux, Prof,³³, 10 Lubos Drgona, MD,³⁴, Nurettin Erben, MD,³⁵, Andrea Gori, MD, ^{36,37}, Julio García Rodríguez, PhD ³⁸, 11 Carolina Garcia-Vidal, MD, ³⁹, Daniele Roberto Giacobbe, MD, ^{18,19}, Anna L. Goodman, MD, ⁴⁰, Petr 12 Hamal, MD,⁴¹, Helena Hammarström, MD,⁴², Christina Toscano, MD, ⁴³, Fanny Lanternier, Prof,⁴⁴, 13 Cornelia Lass-Flörl, Prof, ⁴⁵, Deborah E. A. Lockhart, PhD, ^{46,47}, Thomas Longval, MD, ⁴⁸, Laura Loughlin, 14 MD, ⁴⁹, Tadeja Matos, MD, ⁵⁰, Malgorzata Mikulska, Prof, ^{18,19}, Manjusha Narayanan, FRCPath ⁵¹, Sonia 15 Martín-Pérez, MD, ⁵², Juergen Prattes, MD, ^{1,2,3,4}, Benedict Rogers, MBChB ⁵³, Laman Rahimli, MD, ^{4,5}, 16 Maite Ruiz, PhD,^{54,55}, Emmanuel Roilides, Prof,⁵⁶, Michael Samarkos, Prof,⁵⁷, Ulrike Scharmann, MD,⁵⁸, 17 Uluhan Sili, Prof, 59, Ogun Resat Sipahi, Prof, 60, Alena Sivakova, MD, 61, Joerg Steinmann, Prof, 58,62, Janina 18 19 Trauth, MD, 63, Ozge Turhan, Prof, 64, Jens Van Praet, MD, 65, Antonio Vena, PhD, 18,19, P. Lewis White, Prof, ⁶⁶, Birgit Willinger, Prof, ⁶⁷, Anna Maria Tortorano, PhD, ⁶⁸, Maiken C. Arendrup, Prof, ^{69,70,71}, Philipp 20 Koehler, MD,^{4,5,72*}, Oliver A. Cornely, Prof,^{4,5,72,73*#} - on behalf of the ECMM *Candida* III Study Group\$ 21

22 * Shared Senior authorship

23

25 Affiliations

- 26 ¹Division of Infectious Diseases, Medical University of Graz, Graz, Austria
- 27 ²Biotech Med, Graz
- 28 ³Translational Medical Mycology Research Unit, ECMM Excellence Center for Medical Mycology, Medical
- 29 University of Graz, Graz, Austria
- 30 ⁴University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine,
- 31 Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and Excellence Center for Medical
- 32 Mycology (ECMM), Cologne, Germany
- ³³ ⁵University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Excellence Cluster on
- 34 Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany
- ⁶Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail), UMR_S
 1085, F-35000 Rennes, France
- 37 ⁷Institute of Infection and Immunity, St George's University of London, London, UK
- 38 ⁸Hacettepe University Medical School, Department of Medical Microbiology, Ankara, Turkey
- ⁹Mycology Reference Laboratory, National Centre for Microbiology, Instituto de Salud Carlos III, Madrid, Spain.
- ¹⁰Department of Clinical Mycology, Allergy and Immunology, North Western State Medical University, St Petersburg,
 Russia
- 42 ¹¹Clinic for Infectious and tropical diseases, University Clinical Center of Serbia, Faculty of Medicine, University of
- 43 Belgrade, Belgrade, Serbia
- ¹² Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden
- 45 ¹³ Department of Clinical Microbiology, Karolinska University Hospital, Sweden
- 46 ¹⁴ Canisius Wilhelmina Hospital (CWZ), Medical Microbiology and Infectious Diseases, Nijmegen, the Netherlands
- 47 ¹⁵Center of Expertise in Mycology Radboudumc/CWZ, Nijmegen, the Netherlands.
- 48 ¹⁶ Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, the Netherlands
- 49 ¹⁷ Division of Infectious Diseases and Hospital Epidemiology, University Hospital of Basel, Basel, Switzerland
- ¹⁸ Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy
- ¹⁹ IRCCS Ospedale Policlinico San Martino, Infectious Diseases Unit, Genoa, Italy

- 52 ²⁰Mycology Reference Centre Manchester and Department of Infectious Diseases, Wythenshawe Hospital, Manchester
- 53 University NHS Foundation Trust, Manchester, UK
- ²¹ Division of Evolution, Infection and Genomics, Faculty of Biology, Medicine and Health, University of Manchester,
 UK
- 56 ²² Laboratory of Clinical Microbiology, Department of Microbiology, Immunology and Transplantation, KU Leuven,
- 57 Leuven, Belgium
- 58 ²³ Department of Laboratory Medicine and National Reference Center for Mycosis, UZ Leuven, Leuven, Belgium
- ²⁴ Bursa Uludag University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Bursa,
 Turkey
- 61 ²⁵ Hacettepe University Medical School Department of Infectious Diseases and Clinical Microbiology, Ankara, Turkey
- 62 ²⁶Faculty of Medicine University of Belgrade, Institute of Microbiology and Immunology, Medical Mycology
- 63 Reference Laboratory (MMRL), Belgrade, Institute of Public Health of Vojvodina, Centre for Microbiology Novi
- 64 Sad, Serbia
- 65 ²⁷ Northumbria Healthcare NHS Foundation Trust, Northshields, UK
- 66 ²⁸ Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden
- 67 ²⁹ Laboratory of Parasitology and Mycology, Saint Louis University Hospital, Assistance Publique-Hôpitaux de Paris
- 68 (AP-HP), Paris, France
- ³⁰ Department of Infectious Diseases, CHU de Strasbourg; Université de Strasbourg, Strasbourg, France
- 70 ³¹ Department of Infectious Diseases, Hôpital Saint-Louis, Fernand Widal, Lariboisière, Assistance Publique-Hôpitaux
- 71 de Paris (AP-HP), Paris, France
- 72 ³² Department of Hematology, Amsterdam University Medical Centers, Amsterdam, the Netherlands
- 73 ³³ Department of Parasitology-Mycology-Tropical medicine, CHRU de Tours, Tours, France
- ³⁴Department of Oncohematology, Comenius University and National Cancer Institute, Bratislava, Slovakia
- 75 ³⁵Eskisehir Osmangazi University, Faculty of Medicine, Department of Infectious Disease and Clinical Microbiology,
- 76 Eskisehir, Turkey
- ³⁶Department of Internal Medicine, Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore
 Policlinico, 20122 Milan, Italy.
- ³⁷Department of Pathophysiology and Transplantation and Centre for Multidisciplinary Research in Health Science
 (MACH), University of Milan, 20122 Milan, Italy.

- 81 ³⁸ Microbiology Department, La Paz University Hospital, Madrid, Spain
- 82 ³⁹ Department of Infectious Diseases, Hospital Clinic de Barcelona, Barcelona, Spain.
- ⁴⁰ Department of Infection, Guy's and St Thomas' NHS Foundation Trust) but if space/capacity please add a secondary
- 84 one- which is MRC Clinical Trials Unit at University College London
- ⁴¹ Department of Microbiology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech
 Republic
- ⁴² Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg,
 Gothenburg, Sweden
- ⁴³ Laboratory of Clinical Microbiology and Molecular Biology, Centro Hospitalar de Lisboa Ocidental, Lisboa,
 Portugal
- 91 ⁴⁴ Paris Cité Université, Necker Hospital, APHP, Paris, France

⁴⁵Institute of Hygiene and Medical Microbiology Innsbruck Medical University, Innsbruck Medical University,
 Excellence Center for Medical Mycology (ECMM), Innsbruck, Austria

- ⁴⁶ Department of Medical Microbiology, Aberdeen Royal Infirmary, Foresterhill, Aberdeen AB25 2ZN,, United
 Kingdom
- ⁴⁷ Institute of Medical Sciences, School of Medicine Medical Sciences & Nutrition, University of Aberdeen, Aberdeen
 AB25 2ZD, United Kingdom
- 98 ⁴⁸ Centre Hospitalier de Versailles, Hématologie, Le Chesnay, France
- 99 ⁴⁹ Belfast Health and Social Care Trust, Belfast, United Kingdom
- 100 ⁵⁰ Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
- 101 ⁵¹ Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom
- 102 ⁵² Hospital Nuestra Señora de Sonsoles, Ávila, Spain
- 103 ⁵³ University Hospitals of Leicester NHS Trust, Department of Clinical Microbiology, Leicester, United Kingdom
- 104 ⁵⁴ Unit of Infectious Diseases and Microbiology, Institute of Biomedicine of Seville, University Hospital Virgen del
- 105 Rocio, Seville, Spain
- 106 ⁵⁵ Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, Madrid, Spain.
- 107 ⁵⁶ Hippokration General Hospital, Infectious Diseases Department, Medical School, Aristotle University of
- 108 Thessaloniki, Thessaloniki, Greece

109 110	⁵⁷ 1 st Department of Medicine, Laikon General Hospital, Medical School, National & Kapodistrian University of Athens, Greece
111	⁵⁸ Institute of Medical Microbiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
112 113	⁵⁹ Department of Infectious Diseases and Clinical Microbiology, School of Medicine, Marmara University, Istanbul, Turkey
114	⁶⁰ Ege University Medical School Department of Infectious Diseases and Clinical Microbiology, Izmir, Turkey
115 116	⁶¹ Department of Microbiology of St. Anne's Faculty Hospital and Faculty of Medicine, Masaryk University, Brno, Czech Republic
117 118	⁶² Institute for Clinical Hygiene, Medical Microbiology and Infectiology, Paracelsus Medical University, Klinikum Nürnberg, Nuremberg, Germany
119	⁶³ Department of Medicine II, Section of Infectious Diseases, Justus-Liebig-University Giessen, Giessen, Germany
120 121	⁶⁴ Akdeniz University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Antalya, Turkey
122	⁶⁵ AZ Sint-Jan Brugge Oostende AV, Nephrology and Infectious Diseases, Brugge, Belgium
123	⁶⁶ Public Health Wales, Microbiology Cardiff and Cardiff University, School of Medicine, Cardiff, United Kingdom
124 125	⁶⁷ Division of Clinical Microbiology, Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria
126	⁶⁸ Universita degli Studi di Milano, Milano, Italy
127	⁶⁹ Unit of Mycology, Statens Serum Institut, Copenhagen, Denmark
128	⁷⁰ Department of Clinical Microbiology, Rigshospitalet, Copenhagen, Denmark
129	⁷¹ Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
130	⁷² German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany
131 132	⁷³ University of Cologne, Faculty of Medicine and University Hospital Cologne, Clinical Trials Centre Cologne (ZKS Köln), Cologne, Germany
133	
134	§ <u>ECMM Candida III Study Group contributors:</u>

- 135 Mario Tumbarello¹, Alida Fe Talento², Alba C Ruiz³, Zdenek Racil⁴, Igor Stoma⁵, María Calbacho⁶, Eric
- 136 Van Wijngaerden⁷, Júlia Henriques⁸, Harriett Jordan⁹, Valentina Ferroni¹⁰, Ozlem Koyuncu Ozyurt¹¹,
- 137 Christopher Milacek¹², Robert Krause¹³, Christoph Zurl¹³, Matthijs Backx¹⁴, Ang Li¹⁵, Raphael Seufert¹⁶,
- 138 Rok Tomazin¹⁷, Yael Blankenheim ^{18,19}, Julio Dávila-Valls²⁰, Paloma García-Clemente²¹, Tomas
- 139 Freiberger²², Jochem Buil ²³, Jacques F. Meis ²⁴, Deniz Akyol ²⁵, Hélène Guegan²⁶, Clare Logan ²⁷
- 140 <u>Affiliations</u>
- 141 ¹Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy
- 142 ²Beaumont Hospital Dublin Dublin, Ireland
- ³University and Polytechnic La Fe Hospital, Valencia, Spain
- 144 4 Institut of Hematology and Blood Transfuzion, Prague, Czech Republic
- ⁵Minsk Scintifical and Practical Center of Surgery, Transplantology and Hematology; Gome State University, Misnk,
 Belarus
- 147 ⁶ Hospital 12 Octubre, Hematology, Madrid, Spain
- 148 ⁷Department of General Internal Medicine, UZ Leuven, Leuven, Belgium
- 149 ⁸Laboratory of Clinical Microbiology and Molecular Biology, Centro Hospitalar de Lisboa Ocidental, Lisboa, Portugal
- ⁹Department of Infection, Guy's and St Thomas' NHS Foundation Trust, St Thomas Hospital, Westminister Bridge,
- 151 London, United Kingdom
- ¹⁰Department of Internal Medicine Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy
- 153 ¹¹Akdeniz University, Faculty of Medicine, Department of Medical Microbiology, Antalya, Turkey
- 154 ¹²Department of Internal Medicine II, Division of Pulmonology, Medical University of Vienna, Vienna, Austria
- 155 ¹³Division of Infectious Diseases, Medical University of Graz, Graz, Austria
- 156 ¹⁴Public Health Wales, Microbiology, Cardiff, United Kingdom
- 157 ¹⁵Newcastle Hospitals, Newcastle Upon Tyne, United Kingdom
- ¹⁶ Institute for Clinical Hygiene, Medical Microbiology and Infectiology, Paracelsus Medical University, Klinikum
- 159 Nürnberg, Nuremberg, Germany

- 160 ¹⁷ Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
- ¹⁸University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne; Excellence Cluster on
- 162 Cellular Stress Responses in Aging-Associated Diseases (CECAD); Cologne, Germany
- ¹⁹University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine,
- 164 Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and Excellence Center for Medical
- 165 Mycology (ECMM), Cologne, Germany
- 166 ²⁰Hospital Nuestra Señora de Sonsoles, Ávila Spain
- 167 ²¹La Paz University Hospital, Madrid, Spain
- ²²Centre of Cardiovascular Surgery and Transplantation, Brno, and Faculty of Medicine, Masaryk University, Brno,
 Czech Republic
- 170 ²³Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, the Netherlands
- 171 ²⁴Canisius Wilhelmina Hospital (CWZ), Medical Microbiology and Infectious Diseases, Nijmegen, the Netherlands;
- 172 Center of Expertise in Mycology Radboudumc/CWZ, Nijmegen, the Netherlands.
- 173 ²⁵Ege University Medical School Department of Infectious Diseases and Clinical Microbiology, Izmir, Turkey
- 174 ²⁶ Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail), UMR_S
- 175 1085, F-35000 Rennes, France
- 176 ²⁷Institute of Infection and Immunity, St George's University of London, London, UK
- 177
- 178 <u># Corresponding author:</u>
- 179 Prof. Dr. Martin Hoenigl, MD,
- 180 Division of Infectious Diseases, Department of Internal Medicine,
- 181 Medical University of Graz,
- 182 Auenbruggerplatz 15, 8036-Graz, Austria
- 183 Email: hoeniglmartin@gmail.com

184 Phone: +4331638531425

185

- 186 <u>Alternate Corresponding author:</u>
- 187 Prof. Dr. Oliver A. Cornely
- 188 University of Cologne, Faculty of Medicine and University Hospital Cologne, Translational Research,
- 189 Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), and
- 190 University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal
- 191 Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and
- 192 Excellence Center for Medical Mycology (ECMM), Cologne, Germany
- 193 Herderstraße 52-54
- 194 50931 Cologne, Germany
- 195 Phone: +49 221 478 88795 Fax: +49 221 478 1421445
- 196 E-mail: <u>oliver.cornely@uk-koeln.de</u>

197

198 Author's ORCID

199	Martin HOENIGL	0000-0002-1653-2824
200	Jon SALMANTON-GARCÍA	0000-0002-6766-8297
201	Matthias EGGER	0000-0002-7795-4406
202	Jean-Pierre GANGNEUX	0000-0002-4974-5607
203	Tihana BICANIC	0000-0002-2676-838X
204	Sevtap ARIKAN-AKDAGLI	0000-0001-9807-6764
205	Ana ALASTRUEY-IZQUIERDO	0000-0001-8651-4405
206	Nikolai KLIMKO	0000-0001-6095-7531
207	Volkan ÖZENCI	0000-0002-8069-4027

208	Eelco F J MEIJER	0000-0002-0226-024X
209	Nina KHANNA	0000-0002-2642-419X
210	Matteo BASSETTI	0000-0002-0145-9740
211	Riina RAUTEMAA-RICHARDSON	0000-0002-1071-6040
212	Katrien LAGROU	0000-0001-8668-1350
213	Kai Manuel ADAM	0000-0003-3639-872X
214	Emin Halis AKALIN	0000-0001-7530-1279
215	Murat AKOVA	0000-0002-6904-9473
216	Valentina ARSIC ARSENIJEVIC	0000-0001-8132-3300
217	Avinash AUJAYEB	0000-0002-0859-5550
218	Ola BLENNOW	0000-0002-7167-7882
219	Stephane BRETAGNE	0000-0001-6870-3800
220	Francois DANION	0000-0003-3907-0658
221	Nick DE JONGE	0000-0002-9901-0887
222	Guillaume DESOUBEAUX	0000-0001-7945-9890
223	Lubos DRGONA	0000-0002-5089-3201
224	Nurettin ERBEN	0000-0003-0373-0132
225	Daniele Roberto GIACOBBE	0000-0003-2385-1759
226	Anna GOODMAN	0000-0003-0643-9017
227	Andrea GORI	0000-0001-6587-4794
228	Petr HAMAL	0000-0002-5361-8125
229	Helena HAMMARSTRÖM	0000-0002-5859-1056
230	Cristina TOSCANO	0000-0002-4674-6065
231	Cornelia LASS-FLÖRL	0000-0002-2946-7785
232	Deborah E. A. LOCKHART	0000-0002-4262-3842
233	Tadeja MATOS	0000-0002-5696-1412
234	Małgorzata MIKULSKA	0000-0002-5535-4602
235	Thomas LONGVAL	0000-0002-0254-1519
236	Jens VAN PRAET	0000-0002-7125-7001
237	Sonia Martín-Pérez	0000-0001-5809-7165
238	Juergen PRATTES	0000-0001-5751-9311
239	Laman RAHIMLI	0000-0003-2266-445X
240	Zdeněk RÁČIL	0000-0003-3511-4596

241	Benedict ROGERS	0000-0002-7041-6744
242	Emmanuel ROILIDES	0000-0002-0202-364X
243	Michael SAMARKOS	0000-0001-9630-9712
244	Ulrike SCHARMANN	0000-0001-7689-7799
245	Uluhan SILI	0000-0002-9939-9298
246	Alena SIVAKOVA	0000-0002-9224-4613
247	Jörg STEINMANN	0000-0002-3181-3667
248	Ozge TURHAN	0000-0003-1494-9973
249	Antonio VENA	0000-0002-0697-3992
250	P Lewis WHITE	0000-0003-3056-4205
251	Birgit WILLINGER	0000-0001-7921-5749
252	Anna Maria TORTORANO	0000-0003-2093-8250
253	Maiken Cavling ARENDRUP	0000-0002-4747-0144
254	Philipp KOEHLER	0000 -0002 -7386 -7495
255	Oliver A. CORNELY	0000-0001-9599-3137
256		
257	Contributors:	
258	Julio Dávila -Valls	0000-0002-5185-2073
259	Tomas Freiberger	0000-0001-6532-7053
260	Alida Fe Talento	0000-0003-1271-2550
261	Christopher MILACEK	0000-0002-6924-0075

264 Abstract

265

266 Background

The European Confederation of Medical Mycology (ECMM) collected data on epidemiology, risk
factors, treatment, and outcomes of culture proven candidemia across Europe in order to assess
how adherence to guideline recommendations correlate with outcomes.

270 Methods

Each participating hospital (number of eligible hospitals per country determined by population size) included the first ~10 culture proven candidemia cases after 01-July-2018 and entered data into the ECMM *Candida* III database on the FungiScope[®] platform. EQUAL *Candida* Scores reflecting adherence to recommendations of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Infectious Disease Society of America (IDSA) Guidelines were assessed.

277 Findings

A total of 632 candidemia cases were included from 64 institutions in 20 European countries. 278 Overall 90-day mortality was 42.9% (265/617), and older age, intensive care unit (ICU) admission, 279 280 higher Charlson Comorbidity Index and Candida tropicalis as causative pathogen were independent baseline predictors of mortality in Cox regression analysis. EQUAL Candida Score 281 remained an independent predictor of mortality in the multivariable Cox regression analyses after 282 adjusting for the baseline predictors, even after restricted to cases who survived >7 days after 283 diagnosis (adjusted hazard ratios between 1.075 and 1.089 per 1 point decrease; p<0.0001). Median 284 duration of hospitalization was 16 days following diagnosis of candidemia and was prolonged 285

286	specifically for completion of parenteral therapy in 16% (100/621) of patients. Initial echinocandin
287	treatment was associated with lower overall mortality and also with longer duration of
288	hospitalization among survivors.
289	Interpretation
290	While overall mortality of candidemia was high, our study indicates that adherence to clinical
291	guideline recommendations, reflected by higher EQUAL Candida Scores, may increase survival.
292	Echinocandin treatment was associated with increased overall survival, but also longer duration of
293	hospitalization (hospitalization was prolonged only for completing treatment in 16%).
294	
295	Funding
296	The study was funded by an Investigator Initiated Research Grant from SCYNEXIS, Inc
297	
298	Word Count Abstract: 300
299	
300	Key Words: Candida tropicalis, Candida auris, Candida albicans, Candida parapsilosis,
301	Candida glabrata, mortality, guidelines
302	
303	
304	
305	
306	
307	

308 Research in context

Evidence before this study: Despite advances in management including improved central venous 309 catheter management, candidemia remains associated with high mortality. International guidelines 310 311 for the diagnosis and management of candidemia were created with the ultimate goal of improving patient outcomes and survival, but whether this is actually the result (e.g. also for first-line 312 treatment with echinocandins) has not been comprehensively evaluated. In 2018, the European 313 314 Confederation of Medical Mycology (ECMM) introduced the EQUAL Candida score (ECMM scores to measure quality of disease management) allowing for quantification of guideline 315 316 adherence as a surrogate marker for the quality of diagnostic and therapeutic management. The 317 score was derived from recommendations of the two most prominent guidelines for candidemia, the European Society for Clinical Microbiology and Infectious Diseases (ESCMID) guideline, and 318 the Infectious Diseases Society of America (IDSA) guideline. While this score has been shown to 319 be predictive of mortality in subgroups of candidemia cases in a few small single centre studies, 320 321 larger multicentre evaluations on whether the score and whether following each guideline recommendation (=score variable) separately correlates with clinical outcomes was lacking and 322 not found in the Pub Med database. 323

Added value of this study: This study collected data on epidemiology, risk factors, treatment, and 324 outcomes of culture proven candidemia from 64 institutions in 20 European countries in order to 325 326 assess how adherence to guideline recommendations correlate with outcomes. Patient enrollment per country and number of participating centers were stratified by population size. Overall 90-327 mortality was 42.9%, and older age, intensive care unit (ICU) admission, higher Charlson 328 Comorbidity Index and *Candida tropicalis* as causative pathogen, as well as emerging and rare 329 *Candida* spp. (including *C. auris*) as causative pathogens were independent predictors of mortality 330 in Cox regression analyses. Lower EQUAL Candida Scores, reflecting less adherence to guideline 331 3

recommendations, remained an independent predictor of mortality in the multivariable Cox regression analyses after adjusting for age, ICU admission and rare *Candida spp.* (adjusted hazard ratios between 1.075 and 1.089 per 1 point decrease; p<0.0001). Absence of each diagnostic/therapeutic measure (including absence of initial echinocandin treatment) was accompanied by increased mortality compared to the overall cohort, emphasizing the importance of every single variable in successful management. Initial echinocandin treatment was associated with longer duration of hospitalization among survivors.

339 **Implications of all the available evidence:** While across Europe overall mortality of candidemia in adults remains high at 43%, adherence to clinical guideline recommendations may increase 340 survival. Of note this was also shown for more controversial guideline recommendations, such as 341 342 performance of ophthalmoscopy or echocardiography. Echinocandins may not only be associated with increased overall survival, but also longer duration of hospitalization, including directly 343 causing prolonged hospitalization in 1 out of 7 patients with candidemia, due to the fact that no 344 oral alternatives to azoles are available. This limitation could be overcome by new antifungals with 345 346 oral bioavailability or longer half-life's, which may allow for earlier discharge and outpatient therapy, reducing costs and hospital stay associated risks (e.g., nosocomial infection). 347

348

- 350
- 351
- 352

353 Introduction

354 Invasive candidiasis (IC) including candidemia remains the most frequent invasive fungal infection in the hospital setting affecting males and females alike (1), with around 700,000 cases of IC 355 occurring globally per year (2), 7.07 episodes per 1.000 ICU admissions in Europe (3), and an 356 estimated overall pooled annual incidence rate of 3.88/100,000 population in Europe (4). Known 357 risk factors for developing candidemia/IC in the intensive care unit (ICU) include (abdominal) 358 359 surgery, total parenteral nutrition (TPN), renal replacement therapy, central venous catheter (CVC), broad spectrum antibiotics, diabetes (5, 6), as well as neutropenia, solid organ transplantation, 360 significant liver, respiratory or cardiovascular disease, and intravenous drug use (7). 361

Despite advances in management including first-line treatment with echinocandins and improved CVC management, IC remains associated with high mortality (8). Of approximately 79 cases occurring in Europe per day, an estimated 29 (37%) patients are expected to have fatal outcome at day 30 (4). Predictors of mortality in candidemia include older age, primary source (i.e., not CVC related) and sepsis/septic shock (9) In contrast, early adequate antifungal treatment is efficacious (9), as is consultation by an infectious diseases specialist with a hazard ratio of 0.81 (95% CI 0.73-0.91; p<0.0001) after propensity score weighting (10).

International guidelines for the diagnosis and management of candidemia were created with the ultimate goal of improving patient outcomes and survival, but whether this is actually the result has been rarely evaluated. In 2018, the European Confederation of Medical Mycology (ECMM) introduced the EQUAL scores (ECMM scores to measure quality of disease management) allowing for quantification of guideline adherence as a surrogate marker for the quality of diagnostic and therapeutic management; the EQUAL *Candida* score was the first score published (11). The score was derived from recommendations of the two most prominent guidelines for candidemia, the

376	European Society for Clinical Microbiology and Infectious Diseases (ESCMID) guideline (12),
377	and the Infectious Diseases Society of America (IDSA) guideline (13).
378	In recent single centre studies, the EQUAL candida score (11) was shown to predict mortality in
379	CVC-associated candidemia in general (14), and C. tropicalis candidemia (15), however, larger
380	multicentre evaluations are lacking.
381	Therefore the ECMM (16) designed and conducted the CANDIDA III study - its third pan European
382	multicenter study over the past 25 years (17, 18) - to collect data on epidemiology, risk factors,
383	treatment, and outcomes of culture proven candidemia across Europe, as well as to assess how
384	adherence to guideline recommendations for managing candidemia correlates with outcomes.

386 Methods

387 Study design and participating centers

For this European multicenter observational cohort study, each participating hospital included the first ~10 blood culture proven adult candidemia cases occurring consecutively after July 1st, 2018. Candidemia was, defined according to ESCMID criteria (19). The primary objective was to assess how adherence to guideline recommendations correlate with outcomes. Secondary objectives included to assess epidemiology, risk factors, treatment, and outcome of candidemia across Europe.

To give a realistic picture of candidemia in Europe, the target number of eligible hospitals per 393 394 country was determined by population size. As general guidance, up to a maximum of eight 395 hospitals were allowed for each of the six ECMM countries with populations >50 million (i.e., France, Germany, Italy, Russia, Turkey, and United Kingdom; mean population of these countries 396 is 82.5 million), up to a maximum of four hospitals for each ECMM countries with population >25 397 398 million and <50 million (i.e., Spain and Poland; mean population of these countries 42 million), and up to two hospitals for each of the remaining 16 ECMM countries with population <25 million 399 (mean population 9.4 million) were invited to contribute. Hospitals were recruited by ECMM 400 council representatives of each participating country, or via the EPICOVIDEHA (20) and 401 FungiScope® networks (21) and among the ECMM Global Guidelines contributor and fellow 402 groups (16). 403

Between July 2018 and March 2022, participating centres entered data on patient demographics, risk factors and characteristics, duration of hospitalization (maximum duration of follow-up 90 days), diagnostic procedures, causative *Candida* species, treatment characteristics including antifungal treatment, whether hospital stay was prolonged only for completion of parenteral antifungal treatment, and outcomes, into the ECMM *Candida* Registry - *Candi*Reg – FungiScope[®]

409 (NCT 01731353), which was described previously (21, 22), on <u>www.clinicalsurveys.net</u> (EFS Fall

410 2018 Questback, Cologne, Germany).

411 Statistical analysis and ethics

All statistical analyses were performed using IBM SPSS Statistics 25 (SPSS Inc., Chicago, IL, 412 USA) and R (version 4.3.1; www.r-project.org). Descriptive statistical analysis was performed for 413 most variables including distribution of *Candida* species and prolonged hospital stay for parenteral 414 antifungal treatment. EQUAL Candida Scores (11) reflecting adherence to recommendations of 415 ESCMID and IDSA Guidelines were assessed for every case that provided the prerequisite data in 416 417 for all of the EQUAL *Candida* Score variables. Data were summarized employing frequencies, percentages, median or interquartile range as appropriate. Categorical data were tested using χ^2 or 418 Fisher's exact test if a cell value was under 5, and continuous variables were summarized using 419 420 median (interquartile range, IQR) and compared with Student's t-test / Mann-Whitney's U or ANOVA / Kruskall-Wallis' H, depending on their non-/normal distribution. Two-sided p < .05 was 421 taken as cut-off for statistical significance. 422

Further analyses on EQUAL Candida Scores were restricted to cases who survived at least 7 days 423 424 after diagnosis (n=470), to exclude patients where earlier mortality may have precluded treating 425 physicians from implementing measures recommended in the guidelines, and thereby potentially 426 biasing our results towards lower scores in non-survivors. Scores were divided by the maximum 427 achievable score (19 for those without CVC and 22 for those with CVC) to calculate a proportion 428 of the achievable maximum for each case and compared between survivors and non-survivors. For 429 these EQUAL Candida score proportions, receiver operating characteristic (ROC) curve analyses were performed and area under the curve (AUC) values were calculated. Optimal cutoff was 430 431 determined using Youdens index.

To investigate the association of baseline risk factors with survival, univariable and multivariable 433 Cox proportional hazard models (non-overlapping and non-mutually exclusive variables with 434 p<0.1 included) were estimated for patients without missing data on duration of follow up, with 435 duration of follow up capped at day 180 (n=597). Causative Candida spp. was the only variable 436 that differed between the multivariable models; for one of these models, emerging *Candida* spp. 437 that were defined before(23) (i.e., C. kefyr, C. guilliermondii, C. lusitaniae, C. dubliniensis, C. 438 famata, C. inconspicua, C. rugosa, C. norvegiensis) were grouped together with C. auris into the 439 variable "C. auris and other emerging Candida spp.), while the other model included C. tropicalis, 440 respectively. The proportionality of hazard assumption was evaluated by fitting an interaction 441 between a variable of interest and linear follow-up time. We used the Akaike Information Criterion 442 (AIC) to compare the relative quality of multivariable Cox models for baseline risk factors. 443 We then used a multivariable Cox proportional hazards model to measure the relative hazard for 444 death between different EQUAL Candida scores when adjusting for significant baseline prognostic 445

factors in patients who survived > 7 days and who had data on duration of follow up available (n=443). Lastly, we estimated multivariable Cox models for each variable of the EQUAL *Candida* score adjusted for significant baseline risk factors.

The proportional hazards assumption was tested using the Schoenfeld residuals test for the overall model and individual covariates. The resultant model and all other Cox models did not significantly violate the proportional hazards assumption for individual covariates or the global model. As candidemia diagnosis was the starting point for follow-up and the primary effect of interest (EQUAL *Candida* score) as well as all other covariates were established at baseline, immortal time bias was not considered. The study was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. For the database, retrospective data entry, and data analysis a central ethical approval was obtained at the University of Cologne, Germany (EK 17-485) that indicates that, generally, neither informed consent nor IRB approval individual to each participating hospital would be required. Each participating hospital was required to obtain local IRB confirmation or approval as deemed necessary by local regulations/authorities.

461

462 **Role of the funding source**

The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding authors had both full access to all the data in the study and had final responsibility for the decision to submit for publication.

466 **Results**

467 A total of 632 patients with candidemia were included from 64 institutions in 20 European
468 countries (Figure 1). The study flow is depicted in Figure 2.

Patient demographic and clinical characteristics, risk factors, treatment, and outcomes as well as 469 470 distribution of *Candida* spp. in the overall study cohort, survivors and non-survivors are separately displayed in detail in Supplemental Table 1. The majority (368/632; 58%) were male and median 471 age was 65 years (IQR 53-73). Underlying hematological/oncological malignancy (247/632; 39%), 472 ICU admission (234/632; 37%), and recent major surgery (164/632; 26%), were the most common 473 474 underlying conditions. Candidemia was classified as catheter related bloodstream infection (CRBSI) in 21% (130/632) of cases. In about one third of cases (224/632; 35%) echocardiography 475 was reported, showing cardiac involvement in 11% (25/224) of those examined. Eye exam was 476 reported in 27% (169/632) of cases showing ocular involvement in 11% (19/169) of those 477 478 examined. Overall mortality was 46.4% (286/617); in 37% of those (77/209), investigators 479 attributed death to candidemia; 30-day mortality was 37.6% (232/617), 90-day mortality 42.9% (265/617), 180-day mortality 45.1% (278/617). Median duration of hospitalization was 15 days 480 481 (IQR 4-30 days) after the diagnosis of candidemia. The vast majority (502/620; 81%) received treatment consultation by an infectious diseases or microbiology expert and echinocandins were 482 the first line antifungal treatment in 56% (353/632) of cases. Initial echinocandin treatment was 483 484 associated with longer duration of hospitalization among survivors receiving echinocandins versus 485 other antifungals (median 24 days, IQR 15-40 days vs. median 16 days, IQR 7-33 days; p<0.0001). 486 In those in whom candidemia was treated for at least 14 days, 78% (239/306) survived, compared to 66% (67/102) in those treated for less than 14 days (p=0.01), but who survived beyond day 14 487 488 after diagnosis. Hospital stay was prolonged specifically for the purpose of completing parenteral

489	antifungal treatment in 16% (100/621) by a median of 2 days. Candida albicans was the most
490	common causative pathogen (46%; 287/621) followed by C. glabrata 21% (133/621), C.
491	parapsilosis 13% (83/621), C. tropicalis 7% (46/621), C. krusei and C. auris (each 3%; 16/621).

Informed by univariable Cox regression modelling (**Table 1**), we evaluated two multivariable Cox regression models consisting of three non-overlapping non-mutually exclusive baseline predictors of mortality older age, Charlson Comorbidity Index (CCI) excluding age, ICU admission, and – for model #1 – also *C. tropicalis* as causative pathogen, with the latter being replaced by *C. auris* plus emerging *Candida* spp. for model #2. Informed by AIC values (**Table 1**) we decided to use the baseline parameters of model #1 for further adjustments of the remaining risk models.

Initial echinocandin treatment was associated with lower overall mortality (42%, 148/353) versus those without initial echinocandin therapy (53%, 126/236; p=0.007), also when adjusted for baseline risk factors [adjusted hazard ratio (aHR) 0.56, 95% confidence interval (CI) 0.44 - 0.72; p<0.0001].

502 While consultation by an infectious disease (ID) physician or microbiologist was associated with 503 better survival in the overall cohort (aHR for consultation 0.58, 95%CI 0.44 – 0.7; p=0.0001), this 504 effect started vanishing once patients who had a fatal outcome within two days of diagnosis of 505 candidemia were excluded (aHR 0.71, 95%CI 0.51 – 0.99; p=0.042), with no significant 506 differences in patients who survived for three days or longer, driven in part by the fact that the 507 majority of those patients (421/509, 83%) received consultation.

The EQUAL *Candida* Score was available for 589 cases with candidemia. Scores correlated significantly with duration of hospitalization (r= 0.442; p<0.0001) and – even after exclusion of patients hospitalized \leq 7 days (n=119; EQUAL *Candida* actual/max score proportion median 0.42, IQR 0.27-0.59 in those hospitalized 7 days or shorter *versus* 0.77, IQR 0.63-0.86 in those

hospitalized > 7 days; p<0.0001) - were significantly higher in patients who survived versus those who died (p<0.0001). In those hospitalized >7 days there was no correlation between duration of hospitalization and EQUAL *Candida* actual/max score proportion (Pearson's r=0.054; p=0.26).

Supplemental Figure 1 shows EQUAL *Candida* Scores, Score variables and demographic data in survivors and non-survivors who survived >7 days after candidemia diagnosis. ROC curve analysis revealed an AUC of 0.718 for the proportion of the maximum EQUAL *Candida* score for predicting overall mortality, with an optimal cut-off of 78.1% of the max score (which translates to >14 in those without CVC and >16 in those with CVC). Adjusted HR per point increase in EQUAL *Candida* scores for patients with CVCs and those without are displayed in Figure 3.

Results of the multivariable Cox regression model for risk of mortality with percent decrease in EQUAL *Candida* score in patients who survived longer than 7 days are displayed in **Table 2**. After adjustment for baseline variables (model #1), a decrease in one score point translated to an aHR of 1.075 (95% CI 1.043 - 1.109) in CVC carriers and an aHR of 1.089 (95% CI 1.051 – 1.129) in those without a CVC. ECMM *Candida* scores below the calculated Youden cut-off were associated with an aHR of 3.53 (95% CI 2.01 – 5.98; all p<0.0001).

Table 3 outlines overall mortality rates for each variable of the EQUAL Candida score if absent, 527 followed by results of multivariable Cox regression model evaluating each score variable if absent 528 adjusted for significant baseline risk factors. Absence of each diagnostic/therapeutic measure was 529 530 associated with higher mortality (50.5% - 70.5%) compared to the mortality in the overall cohort (46.4%; 286/617). In the multivariable Cox model for patients who survived > 7 days and adjusted 531 532 for the baseline predictors, absence of ophthalmoscopy, echocardiography, treatment of ≥ 14 days after first negative blood culture, and also absence of stepdown to fluconazole therapy were all 533 significant predictors of mortality with aHRs between 1.71 and 3.64. 534

536 Discussion

We performed a multicenter observational study of candidemia, involving 64 hospitals from 20 537 countries across Europe. Our main finding is that overall 90-day mortality of candidemia remains 538 539 high at 42.9% (265/617). However, adherence to clinical guideline recommendations, as reflected by higher EQUAL Candida scores, was a strong independent predictor of survival. Other findings 540 included that candidemia caused by rare *Candida* spp. may be a relevant independent baseline 541 predictor of survival, in addition to known predictors such as older age and ICU admission. In 542 terms of treatment, initial echinocandin treatment was associated with increased overall survival, 543 544 but also with longer duration of hospitalization.

The overall mortality of 46% found in this study (90-day mortality 43%), of which 37% was 545 directly attributable to candidemia according to investigators, confirms that candidemia is still a 546 major threat to patients and a medical emergency. The rate is as high or even slightly higher than 547 548 rates reported earlier, such as the overall mortality of 43% in Germany, with attributable mortality of 26% (24), and previous ECMM European cohort studies where 37.9% mortality was observed 549 550 between 1997-1999 (that study included neonates and children)(17), and 38.8% observed in surgical ICU patients between 2006-2008 (18). Also, from the United States a 90-day crude 551 mortality of 42.4% for Candida BSI cases were reported, which was more than twice as high than 552 the 17.1% observed among matched controls. Following propensity score-matching, the 553 attributable risk difference for 90-day mortality was 28.4% with hazard ratio (HR) of 2.12 (95% 554 CI, 1.98-2.25, p<0.001) in that study (25). 555

556 Our study identified adherence to international guideline recommendations as a major protective 557 factor. With every point decrease of the EQUAL *Candida* score, reflecting a decrease in adherence 558 to guideline recommendations, hazards increased by 8.9% for patients with CVC and 7.5% for 559 patients without CVC, making survival less likely. Adjustment for the baseline risk fators age, ICU 559

admission, Charlson comorbidity index and *Candida tropicalis* did not change that outcome. In
addition, absence of each diagnostic/therapeutic measure was accompanied by increased mortality
compared to the overall cohort, emphasizing the importance of every single variable in successful
management.

Many known risk factors for Candida infections in the ICU such as previous surgery, TPN, CVC, 564 broad spectrum antibiotics, diabetes (5), neutropenia, or solid organ transplantation (7) were 565 present in relevant proportions of our study population. Age, severe hepatic failure, organ failure 566 567 at the onset of IC, and septic shock (OR 2.12, 95% CI 1.24-3.63, p=0.006) were previously associated with 30-day mortality in candidemia cases (3). In this study, not only did older age, 568 569 higher Charlson comorbidity index and ICU admission stand out as independent baseline predictors 570 of candidemia mortality, but so did candidemia caused by rare Candida tropicalis, and - to a lesser extend – also candidemia causes by emerging or rare Candida spp., particularly C. kefyr and 571 C. guilliermondii but also C. auris. With an increase of species other than Candida albicans (26) 572 and the emergence of new resistant species, including but not limited to C. auris and fluconazole 573 resistant C. parapsilosis (27, 28) this may manifest as major risk factors applicable to larger 574 proportions of candidemia patients in the future (9). While ID consultation was previously shown 575 protective against mortality with a hazard ratio of 0.81 (95% CI 0.73-0.91; p<0.0001) after 576 propensity score weighting (10), consultation by an ID or microbiology expert was protective in 577 578 our study only for avoiding early mortality even after adjusting for baseline risk factors (aHR 0.58, 95% CI 0.44-0.70; p<0.001), a result that may outline the value of early consultation, but also be 579 confounded by the fact that some patients may die before they can receive a consultation. Once 580 patients survived 3 days or longer after diagnosis, ID/microbiology expert consultation did not 581 582 translate to a significant survival benefit.

Finally, our study showed that initial echinocandin treatment was associated with increased overall 583 survival, but also longer duration of hospitalization, as hospitalization was prolonged only for 584 completing parenteral antifungal treatment in 16% (i.e. patients where step-down to fluconazole 585 (29) was not an option). Importantly, this may change in the near future, with a loaded antifungal 586 pipeline (30), that includes rezafungin, an echinocandin with improved penetration into the 587 peritoneal fluid and prolonged half-life allowing once weekly injection, and ibrexafungerp, a novel 588 589 antifungal class with an echinocandin like mechanism of action and excellent oral bioavailability (31), both of may facilitate earlier hospital discharge of those patients in whom stepping down to 590 fluconazole is not an option. 591

Despite its large size (64 institutions in 20 European countries) this multicentre multinational study 592 comes along with some limitations. Not all requested data were available for all patients, and the 593 presented data reflect a real-life scenario with no predefined fungal diagnostic strategies or 594 treatment protocols, potentially affecting the ability to make an early diagnosis and outcomes. In 595 596 addition, EQUAL *Candida* scores may be higher in long-term survivors versus those with an early fatal outcome, given the fact that some of the diagnostic and treatment recommendations take time 597 598 and may not be available in patients with an early fatal outcome. We therefore adjusted our analyses to exclude all patients with a fatal outcome within the first 7 days after diagnosis but cannot rule 599 out that even after this adjustment survival duration may remain a confounder, particularly for 600 601 length of therapy. However, the fact that when the analysis was limited to include only patients surviving more than 14 days, survival remained longer for patients receiving treatment for >14 602 days [78% (239/306) versus 66% (67/102)], indicates that treatment duration may have an impact 603 on longer term survival. Importantly, availability of fungal diagnostics, ID/microbiology 604 consultations and also access to antifungal drugs varies across the world with more limited access 605 in low and middle income countries, limiting generalizability of our results to other settings (32). 606 17

While the geographical distribution of our sample is reflective of Europe including its laboratory capacities (33), it is still likely that those settings with better access to diagnostics and antifungals are overrepresented.

In conclusion, we found that across Europe overall 90-day mortality of candidemia remains high 610 at 43%. Importantly, our study indicates that adherence to clinical guideline recommendations may 611 612 increase survival. Lastly, current first line candidemia treatments with echinocandins are not only associated with increased overall survival, but also longer duration of hospitalization, including 613 directly causing prolonged hospitalization in 1 out of 7 patients with candidemia, due to the fact 614 615 that no oral alternatives to azoles are available. This limitation could be overcome by new antifungals with oral bioavailability or longer half-life, which may allow for earlier discharge and 616 617 outpatient therapy, reducing costs and hospital stay associated risks (e.g., nosocomial infection).

618	Author	contributions:

- 619 Substantial contribution to study concept and design: MH, PK, OC, JSG, JK, MAr, JPG, SAA, TB.
- 620 Substantial contribution to the acquisition of data for the work: All authors.
- 621 Accessed and verified all data: MH, OH and JSG
- 622 Substantial contribution to the statistical analysis or interpretation of data: MH, ME.
- 623 Drafting the manuscript: MH, ME, JSG, PK, OC.
- 624 Critical review of the manuscript and final approval for publication: all authors

625

626 <u>Conflicts of Interest</u>

MH reports grants and research funding from Astellas, Gilead, MSD, Pfizer, Euroimmun, F2G, Pulmocide,
IMMY, Mundipharma and Scynexis.

529 JSG has received lecture honoraria from Gilead and Pfizer, outside of the submitted work.

530 JPG has received lecture honoraria from Gilead, MundiPharma and Pfizer, outside of the submitted work.

631 TB reports receipt of speaker fees, advisory Board fees and research fellowship funding from Gilead

632 sciences, research grants from Pfizer and MSD and advisory Board fees from Mundipharma.

633 SAA reports research grant from Cidara, lecture honoraria from Gilead, and travel grant from Astellas.

- AA-I has received honoraria for educational talks of behalf of Gilead and Pfizer, outside of the submittedwork.
- 636 NK was a speaker for Astellas, Gilead Sciences, Merck/MSD, and Pfizer and an adviser for Gilead Sciences,
- 637 Merck/MSD, and Pfizer, all outside the submitted work.
- 638 KL received consultancy fees from MRM Health, MSD and Gilead, speaker fees from FUJIFILM WAKO,
- 639 Pfizer and Gilead and a service fee from Thermo fisher Scientific and TECOmedical

- 640 NKh is a member of the Gilead, Merck Sharp & Dohme AG (MSD) and Pfizer advisory boards for invasive
- 641 fungal infections, chair of the DSMB of Pulmocide, and reports grants from The Swiss National Science
- 642 Foundation (grant number 32003B 204944 and the National Centre of Competence in Research AntiResist
- 643 Grant 51NF40 180541), outside the submitted work.
- 644 MB reports research grants and/or personal fees for advisor/consultant and/or speaker/chairman from Bayer,
- 645 BioMérieux, Cidara, Cipla, Gilead, Menarini, MSD, Pfizer, and Shionogi.
- 646 MA had research grants from Pfizer, honoraria from Pfizer, Gilead and, Sanofi for contributing educational
- 647 activities which were paid to the university funds; none related with the submitted work.
- 648 VAA reports research funding from Pfizer
- BD reports receipt of speaker fees, advisory Board fees from Gilead sciences, advisory Board fees fromPfizer, outside the submitted work.
- FD declares personal fees from Gilead, Pfizer, outside the submitted work.
- 652 GD has received lecture honoraria from Gilead and Pfizer, outside of the submitted work. He was also 653 invited to symposia and congresses by the two aforementioned companies.
- LD reports lecture honoraria from Pfizer, MSD and Teva, outside the submitted work
- Outside the submitted work, DRG reports investigator-initiated grants from Pfizer, Shionogi, and Gilead
 Italia and speaker fees and/or advisory board fees from Pfizer and Tillotts Pharma.
- FD declares personal fees from Gilead and Pfizer, outside the submitted work.AG reports COI with the
 following companies: JANNSEN, VIIV, MSD, BMS, ABBVIE, GILEAD, NOVARTIS, PFIZER,
 ASTELLAS, ASTRAZENECA, ANGELINI
- 660 CGV reports Grant support from Gilead and MSA, and personal fees from Gilead Science, MSD, Novartis,661 Pfizer, Janssen, Lilly.
- 662 FL reports receipt of speaker fees from Gilead, Pfizer and F2G and advisory board fees from F2G
- 663 MM has received speaker fees from Janssen, Gilead, Mundipharma, MSD and Pfizer
- 664 ORS has received speaker's honorarium from Astellas, Pfizer and Kocak Farma.

ER reports grants to his institutions from Astellas, MSD, Scynexis, Shionogi, GSK, Pfizer, Gilead and
Allergan. He has served as consultant to Amplyx, Astellas, Gilead, MSD, Pfizer, Scynexis, GSK and
Shionogi.

JP has received research funding from MSD and Pfizer and lecture honoraria from Gilead Sciences, Pfizer,
Associates of Cape Cod and Swedish Orphan Biovitrium GmbH, outside of the submitted work.

570 JS has received lecture honoraria from Gilead and Pfizer, outside of the submitted work

671 PLW: Performed diagnostic evaluations and received meeting sponsorship from Associates of Cape Cod,

Bruker, Dynamiker, and Launch Diagnostics; Speaker's fees, expert advice fees and meeting sponsorship

from Gilead; and speaker and expert advice fees from Pfizer and expert advice fees from F2G

BW reports personal fees from MSD, Pfizer, Gilead, Shionogi, Euroimmun, Immy, CapeCod and grants to
her institution from Pfizer, Shionogi and

676 AMT has received lecture honoraria from Gilead

MCA has, over the past 5 years, received research grants/contract work (paid to the SSI) from Amplyx,
Basilea, Cidara, F2G, Gilead, Novabiotics and Scynexis, and speaker honoraria (personal fee) from Astellas,
Chiesi, Gilead, MSD, and SEGES. She is the current chairman of the EUCAST-AFST.

680 PK reports grants or contracts from German Federal Ministry of Research and Education (BMBF) B-FAST 681 (Bundesweites Forschungsnetz Angewandte Surveillance und Testung) and NAPKON (Nationales Pandemie Kohorten Netz, German National Pandemic Cohort Network) of the Network University 682 Medicine (NUM) and the State of North Rhine-Westphalia; Consulting fees Ambu GmbH, Gilead Sciences, 683 684 Mundipharma Resarch Limited, Noxxon N.V. and Pfizer Pharma; Honoraria for lectures from Akademie 685 für Infektionsmedizin e.V., Ambu GmbH, Astellas Pharma, BioRad Laboratories Inc., European 686 Confederation of Medical Mycology, Gilead Sciences, GPR Academy Ruesselsheim, HELIOS Kliniken GmbH, medupdate GmbH, MedMedia, MSD Sharp & Dohme GmbH, Pfizer Pharma GmbH, Scilink 687 Comunicación Científica SC and University Hospital and LMU Munich; Participation on an Advisory 688 689 Board from Ambu GmbH, Gilead Sciences, Mundipharma Resarch Limited and Pfizer Pharma; A pending 690 patent currently reviewed at the German Patent and Trade Mark Office; Other non-financial interests from Elsevier, Wiley and Taylor & Francis online outside the submitted work.MH received research funding 691

21

from Gilead Sciences, Astellas, Mudipharma, Euroimmune, MSD, Pulmocide, Scynexis, F2G and Pfizer,all outside the submitted work.

694 OAC reports grants and personal fees from Actelion, personal fees from Allecra Therapeutics, personal fees 695 from Al-Jazeera Pharmaceuticals, grants and personal fees from Amplyx, grants and personal fees from 696 Astellas, grants and personal fees from Basilea, personal fees from Biosys, grants and personal fees from 697 Cidara, grants and personal fees from DaVolterra, personal fees from Entasis, grants and personal fees from F2G, grants and personal fees from Gilead, personal fees from Grupo Biotoscana, personal fees from 698 699 IQVIA, grants from Janssen, personal fees from Matinas, grants from Medicines Company, grants and 700 personal fees from MedPace, grants from Melinta Therapeutics, personal fees from Menarini, grants and 701 personal fees from Merck/MSD, personal fees from Mylan, personal fees from Nabriva, personal fees from 702 Noxxon, personal fees from Octapharma, personal fees from Paratek, grants and personal fees from Pfizer, 703 personal fees from PSI, personal fees from Roche Diagnostics, grants and personal fees from Scynexis, 704 personal fees from Shionogi, grants from DFG, German Research Foundation, grants from German Federal 705 Ministry of Research and Education, grants from Immunic, personal fees from Biocon, personal fees from 706 CoRe Consulting, personal fees from Molecular Partners, from MSG-ERC, from Seres, other from Wiley 707 (Blackwell), outside the submitted work.

All other authors declare no conflict of interest for this study.

709 Funding

- 710 The study was partly funded by an Investigator Initiated Research Grant from Scynexis (PIs Hoenigl and
- 711 Cornely). The funder had no influence on the study design or on the analysis of the results.

712 Data sharing statement:

713 Case level data will be available from the authors by request.

Table 1. Univariable and multivariable Cox regression model for predictors of mortality in candidemia
 (n=597)

Variable	Univariable hazard ratio	95% CI	p-value
Demographics			
Male, Sex	1.19	0.93 - 1.52	0.160
Age	1.37	1.18 - 1.60	<0.0001
Coexisting conditions			
BMI≥30	1.01	0.74 - 1.39	0.946
SOT	0.61	0.25 - 1.49	0.278
Haematological/Oncological malignancy	1.13	0.89 - 1.44	0.323
Neutropenia (<500/microL)	1.06	0.75 - 1.50	0.754
Major surgery including abdominal surgery	0.95	0.72 – 1.25	0.704
Diabetes mellitus (Type I or II)	0.99	0.75 - 1.31	0.930
Clinical factors			
ICU admission	1.71	1.34 - 2.17	<0.0001
CRBSI	0.89	0.66 - 1.19	0.426
Prosthetic heart valve	1.00	0.71 - 1.42	0.981
Mechanical ventilation	1.32	1.02 - 1.71	0.033
ECMO	1.32	0.65 - 2.670	0.441
TPN	0.83	0.62 - 1.11	0.212
Charlson Comorbidity Index	1.09	1.05 - 1.13	<0.0001
Charlson Comorbidity Index (excluding age)	1.07	1.03 – 1.11	0.0019
Candida spp. (n)			
C. albicans (274)	0.92	0.72 - 1.16	0.475

C. glabrata (127)	0.88	0.65 - 1.18	0.385
C. parapsilosis (80)	0.98	0.70 - 1.38	0.916
C. tropicalis (44)	1.78	1.16 - 2.57	0.0071
C. krusei (12)	0.84	0.31 - 2.25	0.726
C. auris (15)	1.39	0.69 - 2.81	0.357
C. dubliniensis (9)	0.69	0.22 - 2.15	0.519
C. guilliermondii (6)	3.64	1.62 - 8.18	0.0018
C. lusitaniae (5)	1.23	0.39 - 3.84	0.719
C. kefyr (5)	3.27	1.22 - 8.80	0.019
Other Candida Species (9)*	0.75	0.24 - 2.33	0.617
C. auris and other emerging Candida species (46)\$	1.54	1.03 - 2.30	0.034
C. auris and rare Candida species (49)§	1.39	0.93 - 2.09	0.108
Clinical course (i.e., not baseline variables)			
Mixed fungal infections	2.45	0.57-10.5	0.226
Initial Echinocandin treatment	0.55	0.44 - 0.70	<0.0001
Infection consultation (ID or microbiology)	0.56	0.43 - 0.74	<0.0001
Model #1 (AIC=3172)			_
Variables	Multivariable hazard ratio	95% CI	p-value
Age	1.34	1.15 – 1.57	0.0002
ICU	1.83	1.44 - 2.33	<0.0001
Charlson Comorbidity Index (excluding Age)	1.07	1.02 - 1.12	0.0035

C. tropicalis	1.71	1.15 - 2.55	0.0085
Model #2 (AIC = 3175)	Multivariable hazard ratio	95% CI	p-value
Variables			
Age	1.39	1.18 – 1.63	<0.0001
ICU	1.77	1.39 - 2.25	<0.0001
<i>C.auris</i> and other emerging <i>Candida</i> species §	1.50	0.99 - 2.26	0.056
Charlson Comorbidity Index (excluding age)	1.06	1.02 – 1.11	0.0056

Abbreviations: AIC = Akaike Information Criterion; BMI = body mass index; CRBSI = catheter related bloodstream infection:, ECMO = extracorporeal membrane oxygenation; ICU = intensive care unit; ID = infectious diseases; SOT = solid organ transplant; TPN = total parenteral nutrition

* Others include: Candida norvegensis (n=1), Candida digboensis (n=1), Candida rugosa (n=3), Candida pelliculosa (n=2), Candida inconspicua (n=2; one coinfected with C. norvegensis), and Candida famata (n=1)

\$ C. auris and C. kefyr, C. guilliermondii, C. lusitaniae, C. dubliniensis , C. famata, C. inconspicua, C. rugosa, C. norvegensis.

 \S C. auris and all other Candida spp. with 10 or fewer isolates.

- 717 **Table 2.** Multivariable cox regression (adjusted for age, ICU, Charlson Comorbidity Index (excluding age),
- *Candida tropicalis*) model for risk of mortality with percent decrease in EQUAL *Candida* score in patients
 who survived longer than 7 days (n= 443)

Variable	Multivariable hazard ratio	95% CI	p-value
EQUAL <i>Candida</i> score risk per % of actual/max score proportion decrease	1.016	1.009 - 1.023	<0.0001
EQUAL <i>Candida</i> score risk per 10% of actual/max score proportion decrease	1.175	1.099 – 1.257	<0.0001
* Risk per decrease in point <i>Candida</i> score for CVC carriers	1.075	1.043 - 1.109	<0.0001
Risk per decrease in point <i>Candida</i> score for patients without CVC	1.089	1.051 – 1.129	<0.0001
°EQUAL <i>Candida</i> score ≤78.1% of max Score	3.53	2.01 - 5.98 -	<0.0001
Risk reduction comparingmaximum and minimum <i>Candida</i> score	0.20	0.10 - 0.39	<0.0001

Table explanation:

* With CVC max *Candida* score = 22 points which refers to 4.5% per point

Without CVC max *Candida* score = 19 points which refers to 5.3% per point


° Multivariable hazard ratio for calculated threshold with max. sensitivity/specificity for prediction of death


Abbreviation: *CVC* = *central venous catheter*

- 721 Table 3. Absolute mortality rates for EQUAL score variables if absent, as well as multivariable Cox
- regression models [each variable adjusted for age, ICU, Charlson comorbidity index (excluding age),
- 723 *Candida tropicalis*] for score variables for prediction of mortality in patients with invasive candidiasis
- 724 who survived longer than seven days (n=443)

	Absolute mortality rates			
Absence of Diagnostic measures	<u> </u>			
Initial blood cultures of 40mL	58.	2% (32/55)		
Species identification	58.1% (25/43)			
Susceptibility testing	60.0% (53/89)			
Ophthalmoscopy	58.6% (224/382)			
Echocardiography	56.6% (189/334)			
Absence of Treatment measures				
Start echinocandin treatment	53.0% (132/249)			
Stepdown to fluconazole	55.2% (229/415)			
Treatment for 14d after first BC neg.	70.5% (196/278)			
$CVC removal \le 24h^*$	50.5% (194/384)			
	Multivariable hazard ratio			
		95% CI	p-value	
Absence of Diagnostic measures				
Initial blood cultures of 40 mL	1.26	0.69 - 2.30	0.455	
Species identification	1.46	0.76 - 2.82	0.302	
Susceptibility testing	1.40	0.86 - 2.29	0.260	
Ophthalmoscopy	2.19	1.55 - 3.11	<0.0001	
Echocardiography	1.77	1.27 - 2.46	0.0006	
Follow up BC until negative	1.28	0.91 - 1.80	0.159	
Absence of Treatment measures				
Start echinocandin treatment	1.23	0.874 - 1.72	0.260	

Stepdown to fluconazole	1.71	1.17 - 2.50	0.0058
Treatment for 14d after first BC neg.	3.64	2.62 - 5.06	<0.0001
CVC removal $\leq 24h^*$	1.41	0.96 - 2.05	0.078
CVC removal > 24h <72h	1.21	0.77 – 1.90	0.417
Abbreviations: BC, blood culture; CVC, *CVC carriers only	central venous catheter.		





728 Figure 2. Study flowchart.






Figure 3. Adjusted* hazard ratios per point increase in EQUAL Candida scores for patients with central venous catheters (CVCs, blue) and those



736 without (orange), as well as Boxplots



References

1. Egger M, Hoenigl M, Thompson GR, 3rd, Carvalho A, Jenks JD. Let's talk about Sex Characteristics - as a Risk Factor for Invasive Fungal Diseases. Mycoses. 2022;65(6):599-612.

2. Bongomin F, Gago S, Oladele RO, Denning DW. Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision. Journal of fungi (Basel, Switzerland). 2017;3(4):10.3390/jof3040057.

3. Bassetti M, Giacobbe DR, Vena A, Trucchi C, Ansaldi F, Antonelli M, et al. Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project. Crit Care. 2019;23(1):219.

4. Koehler P, Stecher M, Cornely OA, Koehler D, Vehreschild M, Bohlius J, et al. Morbidity and mortality of candidaemia in Europe: an epidemiologic meta-analysis. Clin Microbiol Infect. 2019;25(10):1200-12.

5. Muskett H, Shahin J, Eyres G, Harvey S, Rowan K, Harrison D. Risk factors for invasive fungal disease in critically ill adult patients: a systematic review. Crit Care. 2011;15(6):R287.

6. Hoenigl M, Seidel D, Sprute R, Cunha C, Oliverio M, Goldman GH, et al. COVID-19-associated fungal infections. Nat Microbiol. 2022;7(8):1127-40.

7. Keighley CL, Pope A, Marriott DJE, Chapman B, Bak N, Daveson K, et al. Risk factors for candidaemia: A prospective multi-centre case-control study. Mycoses. 2021;64(3):257-63.

8. Strollo S, Lionakis MS, Adjemian J, Steiner CA, Prevots DR. Epidemiology of Hospitalizations Associated with Invasive Candidiasis, United States, 2002-2012(1). Emerg Infect Dis. 2016;23(1):7-13.

9. Puig-Asensio M, Padilla B, Garnacho-Montero J, Zaragoza O, Aguado JM, Zaragoza R, et al. Epidemiology and predictive factors for early and late mortality in Candida bloodstream infections: a population-based surveillance in Spain. Clin Microbiol Infect. 2014;20(4):O245-54.

10. Mejia-Chew C, O'Halloran JA, Olsen MA, Stwalley D, Kronen R, Lin C, et al. Effect of infectious disease consultation on mortality and treatment of patients with candida bloodstream infections: a retrospective, cohort study. Lancet Infect Dis. 2019;19(12):1336-44.

11. Mellinghoff SC, Hoenigl M, Koehler P, Kumar A, Lagrou K, Lass-Florl C, et al. EQUAL Candida Score: An ECMM score derived from current guidelines to measure QUAlity of Clinical Candidaemia Management. Mycoses. 2018;61(5):326-30.

12. Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012;18 Suppl 7:19-37.

13. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1-50.

14. El Zakhem A, El Eid R, Istambouli R, Tamim H, Kanj SS. The Utility of EQUAL Candida Score in Predicting Mortality in Patients with Candidemia. J Fungi (Basel). 2022;8(3).

15. Leepattarakit T, Tulyaprawat O, Vongseenin C, Rujirachun P, Wattanachayakul P, Phichinitikorn P, et al. EQUAL Candida score, an effective tool for predicting the outcomes of Candida tropicalis candidaemia: A retrospective cohort study. Mycoses. 2022;65(4):473-80.

16. Hoenigl M, Gangneux JP, Segal E, Alanio A, Chakrabarti A, Chen SC, et al. Global Guidelines and Initiatives from the European Confederation of Medical Mycology to improve Patient Care and Research Worldwide: New Leadership is about Working Together. Mycoses. 2018;61(11):885-94.

17. Tortorano AM, Peman J, Bernhardt H, Klingspor L, Kibbler CC, Faure O, et al. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 2004;23(4):317-22.

18. Klingspor L, Tortorano AM, Peman J, Willinger B, Hamal P, Sendid B, et al. Invasive Candida infections in surgical patients in intensive care units: a prospective, multicentre survey initiated by the European Confederation of Medical Mycology (ECMM) (2006-2008). Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2015;21(1):87.e1-.e10.

19. Cuenca-Estrella M, Verweij PE, Arendrup MC, Arikan-Akdagli S, Bille J, Donnelly JP, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clin Microbiol Infect. 2012;18 Suppl 7:9-18.

20. Salmanton-García J, Busca A, Cornely OA, Corradini P, Hoenigl M, Klimko N, et al. EPICOVIDEHA: A Ready to Use Platform for Epidemiological Studies in Hematological Patients With COVID-19. Hemasphere. 2021;5(7):e612.

21. Seidel D, Durán Graeff LA, Vehreschild M, Wisplinghoff H, Ziegler M, Vehreschild JJ, et al. FungiScope([™]) -Global Emerging Fungal Infection Registry. Mycoses. 2017;60(8):508-16.

22. Koehler P, Arendrup MC, Arikan-Akdagli S, Bassetti M, Bretagne S, Klingspor L, et al. ECMM CandiReg-A ready to use platform for outbreaks and epidemiological studies. Mycoses. 2019;62(10):920-7.

23. Papon N, Courdavault V, Clastre M, Bennett RJ. Emerging and emerged pathogenic Candida species: beyond the Candida albicans paradigm. PLoS Pathog. 2013;9(9):e1003550.

24. Cornely FB, Cornely OA, Salmanton-García J, Koehler FC, Koehler P, Seifert H, et al. Attributable mortality of candidemia after introduction of echinocandins. Mycoses. 2020;63(12):1373-81.

 Mazi PB, Olsen MA, Stwalley D, Rauseo AM, Ayres C, Powderly WG, et al. Attributable Mortality of Candida Bloodstream Infections in the Modern Era: A Propensity Score Analysis. Clin Infect Dis. 2022.
 Pappas PG, Lionakis MS, Arendrup MC, Ostrosky-Zeichner L, Kullberg BJ. Invasive candidiasis. Nat Rev Dis Primers. 2018;4:18026.

27. Alcoceba E, Gómez A, Lara-Esbrí P, Oliver A, Beltrán AF, Ayestarán I, et al. Fluconazole-resistant Candida parapsilosis clonally related genotypes: first report proving the presence of endemic isolates harbouring the Y132F ERG11 gene substitution in Spain. Clin Microbiol Infect. 2022;28(8):1113-9.

28. Chowdhary A, Tarai B, Singh A, Sharma A. Multidrug-Resistant Candida auris Infections in Critically III Coronavirus Disease Patients, India, April-July 2020. Emerg Infect Dis. 2020;26(11):2694-6.

29. Moreno-García E, Puerta-Alcalde P, Gariup G, Fernández-Ruiz M, López Cortés LE, Cuervo G, et al. Early Stepdown From Echinocandin to Fluconazole Treatment in Candidemia: A Post Hoc Analysis of Three Cohort Studies. Open Forum Infectious Diseases. 2021;8(6):ofab250.

30. Hoenigl M, Sprute R, Arastehfar A, Perfect JR, Lass-Flörl C, Bellmann R, et al. Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action. Expert Opin Investig Drugs. 2022;31(8):795-812.

31. Hoenigl M, Sprute R, Egger M, Arastehfar A, Cornely OA, Krause R, et al. The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin. Drugs. 2021; 81(15):1703-1729.

32. Driemeyer C, Falci DR, Oladele RO, Bongomin F, Ocansey BK, Govender NP, et al. The current state of clinical mycology in Africa: a European Confederation of Medical Mycology and International Society for Human and Animal Mycology survey. The Lancet Microbe. 2022;3(6):e464-e470.

33. Salmanton-Garcia JH, M; Gagneux, JP, Segal, E; Alstruey-Izquierdo, A; Arikan-Akdagli, S; Özenci, V; Vena, A; Cornely, OA. The current state of laboratory mycology in Europe: A European Confederation of Medical Mycology survey. Lancet Microbe. 2022.